Amiodarone in prevention of atrial fibrillation after coronary artery bypass grafting
- Author:
Qing-Qi HAN
1
Author Information
1. Department of Cardiothoracic Surgery
- Publication Type:Journal Article
- From:
Academic Journal of Second Military Medical University
2006;27(9):973-976
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the role of amiodarone in preventing atrial fibrillation after coronary artery bypass grafting (CABG). Methods: Totally 184 patients receiving CABG under cardiopulmonary bypass (CPB) were randomly divided into amiodarone group (n=94) and placebo group (n=90), and patients in each group were further divided into ≥ 60 years and < 60 years subgroups. Patients in amiodarone group received routine drugs + amiodarone and those in placebo group received routine drugs + placebo. Results: The overall incidence of postoperative AF (paroxysmal and persistent) was significantly higher in the placebo group compared with the amiodarone group (32. 2% vs 6. 4%, P<0. 01, OR=7.0). The incidences of postoperative AF were similar in patients aged <60 years between the placebo group and the amiodarone group, but were significantly different in patients aged ≥ 60 (P<0.05 or P<0.01). The postoperative AF incidence was significantly different between 2 age subgroups (P<0.05 or P<0.01) in the placebo group, but not in amiodarone group. Conclusion: Amiodarone can effectively prevent post-operative AF, especially for patients aged ≥ 60 years. Amiodarone should be recommended to patients receiving CABG who aged ≥ 60 years.
